Haussier
Pfizer's stock rises 2.43% to $25.25 amid positive analyst outlook.
Ce briefing n’est pas encore disponible dans cette langue — version anglaise affichée.
Pfizer's stock price increased by 2.43% to $25.25, following positive analyst assessments. RBC Capital upgraded Pfizer's rating to 'Sector Perform' with a $25.00 price target, citing improved valuation and upcoming catalysts. Additionally, the Swiss National Bank increased its stake in Pfizer by 7.1%, now holding approximately 16.7 million shares valued at $468.5 million.
Points clés
- RBC Capital upgrades Pfizer's rating to 'Sector Perform' with a $25.00 price target, citing improved valuation and upcoming catalysts.
- Swiss National Bank increases its stake in Pfizer by 7.1%, now holding approximately 16.7 million shares valued at $468.5 million.
- Pfizer's stock price rises 2.43% to $25.25 amid positive analyst outlook.
Sources
Généré par IA à partir de sources d'actualités publiques. Ceci n'est pas un conseil financier.
